Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredients. The company is headquartered in Rancho Cucamonga, California and currently employs 1,976 full-time employees. The company went IPO on 2014-06-25. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The firm manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. The company manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. The company is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.